Nasogastric Securement Device Market by Product Type (Adhesive Securement Devices, Clip Locking Devices, Suture Methods), Material (Polyvinyl Chloride, Silicone, Thermoplastic Elastomers), Application, End User, Distribution Channel - Global Forecast 2026

The Nasogastric Securement Device Market was valued at USD 315.27 million in 2025 and is projected to grow to USD 346.65 million in 2026, with a CAGR of 9.10%, reaching USD 580.27 million by 2032.

Nasogastric securement devices are becoming a patient-safety and workflow cornerstone as clinicians demand reliability, comfort, and consistency

Nasogastric tube therapy remains a daily reality across emergency care, perioperative units, critical care, and long-term facilities, yet securement is still one of the most underestimated determinants of therapy continuity. A nasogastric securement device does more than keep a tube in place; it reduces accidental dislodgement, supports accurate tip positioning over time, and helps prevent avoidable interruptions to feeding, decompression, or medication delivery. In practice, securement also shapes patient comfort, clinician workload, and the frequency of reinsertions that can elevate risk and consume scarce bedside time.

In recent years, healthcare organizations have faced a convergence of forces that make securement decisions more consequential. Higher-acuity patient populations, increased focus on reducing preventable harm, and the normalization of evidence-based device management have raised the bar for performance and documentation. At the same time, staffing constraints and rising throughput expectations are pushing teams to choose devices and protocols that are easy to apply consistently, maintain adhesion under challenging conditions, and minimize skin trauma during wear and removal.

Against this backdrop, the nasogastric securement device landscape is evolving from a largely commoditized accessory category into a clinically meaningful product segment where materials science, human factors engineering, and procurement strategy intersect. The executive summary that follows frames the major shifts influencing product requirements and buying behaviors, explains how tariff-related policy changes could reshape cost structures and supply chains, and distills segmentation and regional patterns that decision-makers can use to prioritize near-term actions.

From tape to engineered systems, the market is shifting toward skin-safe materials, standardized protocols, and value defined by total clinical workload

The landscape is undergoing a clear transition from basic adhesion toward engineered securement systems that better manage motion, moisture, and long dwell times. Historically, many facilities relied on generic tape-based approaches or simple nasal dressings. While inexpensive and familiar, these approaches can perform inconsistently across skin types, perspiration levels, and clinical environments. As organizations standardize care pathways, variability is increasingly viewed as an operational risk, which is accelerating adoption of devices designed specifically for nasogastric tubes with defined application steps and predictable removal characteristics.

Another transformative shift is the growing influence of skin integrity and medical adhesive-related injury prevention on purchasing decisions. Clinicians and wound-care teams are increasingly attentive to erythema, blistering, and skin stripping, particularly in older adults, neonates, and patients receiving vasoactive therapies. Consequently, manufacturers are investing in silicone-based adhesives, hydrocolloid interfaces, and multi-layer constructions that distribute stress and reduce shear. This focus extends beyond the adhesive itself to include contouring that fits varied nasal anatomies and flexible components that absorb tugging without transferring force directly to the nares.

Digitalization is also reshaping expectations, even for a category that appears simple. Barcode-driven inventory management, documentation requirements, and protocol adherence initiatives are nudging suppliers toward clearer labeling, standardized kits, and compatibility with broader enteral access policies. In parallel, infection prevention considerations are influencing product design and evaluation, including cleanliness of application, resistance to contamination during routine care, and the practicality of replacement schedules in high-burden units.

Finally, market behavior reflects a shift in how value is defined. Decision-makers are moving from unit cost comparisons to total-cost thinking that incorporates nursing time, frequency of retaping, likelihood of dislodgement, patient experience, and the downstream impact of therapy interruption. This change favors products that may carry a higher upfront cost but demonstrably reduce rework and improve consistency. As a result, competitive differentiation is increasingly tied to clinical evidence, usability testing, and the ability to support facility-wide standardization across multiple departments.

Tariffs expected in 2025 could reshape costs and sourcing, pushing suppliers and providers toward resilience, dual sourcing, and design-to-value decisions

United States tariff dynamics anticipated for 2025 introduce a practical layer of uncertainty for both manufacturers and healthcare buyers, especially where upstream inputs, packaging components, or finished goods involve cross-border sourcing. Even when a device is assembled domestically, adhesives, films, liners, and specialty nonwovens may have international supply footprints. As tariffs alter landed costs, companies may experience margin pressure that cannot be absorbed indefinitely, pushing selective price adjustments, minimum order thresholds, or revised contract structures.

These pressures are likely to accelerate supply chain reconfiguration. Manufacturers may qualify secondary suppliers for critical materials, shift conversion activities closer to end markets, or redesign components to reduce dependence on tariff-exposed inputs. While these moves can improve resilience, they also create short-term operational friction: revalidation of materials, updated quality documentation, and change-control processes that must satisfy regulatory and customer requirements. For healthcare providers, that translates into a higher probability of product substitutions, backorder risk during transitions, and more frequent requests for value analysis reviews.

At the purchasing level, tariffs can influence how contracts are negotiated and how inventory buffers are managed. Providers may favor suppliers with diversified sourcing, transparent continuity plans, and stable lead times rather than those competing solely on price. Additionally, group purchasing strategies may evolve toward dual-award models that reduce single-source dependency for high-use items, including securement devices that are integral to enteral therapy protocols.

Over the same period, tariffs may indirectly shape innovation priorities. If certain advanced materials become more expensive or difficult to source, suppliers may invest in alternative adhesive chemistries, different liner systems, or modular designs that maintain clinical performance while improving cost predictability. In effect, tariff-driven constraints can act as a catalyst for design-to-value engineering, with winning products offering both clinical reliability and a supply chain narrative that reassures risk-averse health systems.

Segmentation reveals how care setting, device design, and adhesive materials jointly determine adoption, performance expectations, and standardization success

Segmentation patterns reveal that adoption is strongly shaped by where care is delivered and which patient needs dominate. In hospitals, securement choices are often driven by protocol standardization across emergency, ICU, and surgical units, where rapid placement and high movement risk demand devices that hold under sweat, oral care, and frequent repositioning. By contrast, ambulatory surgery centers and outpatient environments tend to prioritize quick application and clean removal, since dwell times may be shorter and patient turnover is high. Home healthcare introduces a different set of requirements, where caregiver variability and limited clinical oversight make intuitive application and clear wear-time guidance critical.

Product type distinctions also matter in how buyers define acceptable performance. Tape-based approaches persist where budgets are constrained or where staff training favors familiar routines, yet the trend is toward dedicated securement devices that provide a structured method of anchoring the tube while reducing skin trauma. Within dedicated devices, designs that combine an adhesive base with a tube-holding mechanism can reduce micro-movements that otherwise lead to discomfort and repeated retaping. Furthermore, product decisions increasingly reflect the anticipated duration of therapy, with longer dwell times amplifying the importance of moisture management, edge lift resistance, and gentle removal.

Material segmentation underscores the growing preference for skin-friendly adhesion without sacrificing hold strength. Acrylic adhesives remain common due to strong tack and broad availability, but silicone-based solutions are gaining attention for their gentler removal profiles, particularly in populations at risk of skin injury. Hydrocolloid interfaces, whether used alone or as part of layered constructions, can help buffer shear and provide a more forgiving contact surface. These choices are rarely made in isolation; they are evaluated alongside patient age, comorbidities, and the likelihood of frequent reapplications.

End-user workflow segmentation highlights how procurement aligns with staffing realities. High-intensity units may value devices that minimize steps and reduce the need for frequent checks, whereas wards with lower acuity may accept more routine maintenance if products are cost-effective and training is straightforward. Across segments, a consistent insight emerges: products that reduce variability in application and replacement schedules tend to perform better in real-world use, because they fit into repeatable routines that busy teams can sustain.

Regional differences in procurement, regulation, and care delivery shape securement adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics show that clinical practice norms, procurement models, and regulatory expectations strongly shape securement preferences. In the Americas, emphasis on reducing preventable harm and documenting device-related complications supports demand for products that can be standardized across multiple departments. Large integrated delivery networks often pursue harmonized protocols, which elevates the value of training materials, consistent supply availability, and products that perform across varied patient populations.

In Europe, the market is influenced by strong attention to patient comfort, skin integrity, and evidence-based practice, alongside diverse country-level purchasing frameworks. Facilities frequently balance clinical preferences with structured tender processes that prioritize compliance documentation, product consistency, and sustainable supply. This environment can favor suppliers that can demonstrate reliable performance, clear instructions for use, and support for multi-language training and labeling.

The Middle East & Africa region presents a mix of high-investment healthcare hubs and resource-variable systems. In well-funded centers, demand often aligns with international standards and a focus on premium patient experience, which can accelerate adoption of engineered securement devices. Elsewhere, procurement may be more price-sensitive and dependent on distributor networks, making availability, shelf-life management, and simplified SKU portfolios particularly important.

In Asia-Pacific, growth in hospital capacity, expanding critical care capabilities, and increasing adoption of standardized clinical protocols are shaping demand. Markets with advanced healthcare infrastructure tend to evaluate securement devices through patient-safety and nursing-efficiency lenses, while developing markets may prioritize cost-effective solutions that still offer improved reliability over ad hoc methods. Across the region, local manufacturing capabilities and country-specific regulatory pathways can influence which products scale quickly and how suppliers structure partnerships.

Competition is intensifying as leading firms pair adhesive science and usability design with implementation support and resilient supply commitments

Company positioning in nasogastric securement devices increasingly reflects a balance between clinical credibility, materials expertise, and supply reliability. Established medical device and consumables firms leverage broad hospital relationships to bundle securement with enteral feeding portfolios, using standardized training and contracting strength to support conversion initiatives. These companies tend to compete on breadth, consistent quality systems, and the ability to support multi-site rollouts with stable logistics.

Specialized adhesive and dressing innovators compete by elevating skin safety and comfort as primary value propositions. Their differentiation often lies in proprietary adhesive formulations, layered dressings that mitigate shear, and designs that reduce edge lift under moisture. As skin integrity becomes a higher priority, these firms can win evaluations by aligning with wound-care stakeholders and demonstrating removal characteristics that reduce skin trauma.

Mid-sized and emerging players frequently compete through human factors design and targeted clinical workflows. Examples include devices that simplify application steps, improve tube centering, or enable quick inspection without full replacement. These companies may be particularly agile in responding to frontline feedback, piloting revisions, and tailoring packaging or kit configurations to specific care settings.

Across the competitive landscape, credibility is increasingly earned through practical evidence, not just claims. Buyers look for clear instructions, consistency across lots, and responsiveness when performance varies across patient populations. Companies that pair product performance with implementation support-training modules, competency checklists, and protocol templates-tend to become preferred partners, especially when health systems aim to reduce variability and improve compliance.

Leaders can win by standardizing securement as a system, designing for real-world failure modes, and building tariff-resilient sourcing and metrics-driven adoption

Industry leaders can strengthen outcomes and commercial performance by treating securement as a system rather than a standalone product. Standardizing application and replacement protocols across units reduces variation that can undermine even the best device. Therefore, aligning nursing leadership, wound-care experts, and value analysis stakeholders around a shared definition of success-secure hold, skin protection, and minimal rework-creates a clearer path to product selection and sustained compliance.

Manufacturers should invest in design choices that directly address the most common real-world failure modes: moisture exposure, facial contours, patient agitation, and frequent handling during oral or nasal care. Improving edge lift resistance, enabling micro-adjustments without full removal, and providing clear visual cues for placement can materially reduce retaping frequency. In parallel, training should be treated as a product feature, delivered through concise, role-specific materials that support rapid onboarding and consistent technique.

On the commercial and operational side, tariff-related uncertainty makes supply resilience a differentiator. Companies should map tariff exposure across raw materials and converters, qualify alternates for high-risk inputs, and communicate continuity plans proactively to procurement teams. Providers, in turn, can reduce risk by avoiding single-source dependencies, building substitution guidance into policies, and establishing clinically validated alternates before disruptions occur.

Finally, leaders should adopt a measurement mindset that connects securement decisions to operational outcomes. Tracking dislodgement events, retaping frequency, skin complications, and time spent on maintenance creates a feedback loop for continuous improvement. When these metrics are used in product evaluations and post-implementation reviews, organizations can move beyond anecdotal preferences and build a durable case for standardization that benefits patients and staff alike.

A triangulated methodology combining clinician input, procurement perspectives, and product documentation builds decision-ready insight into securement needs

The research methodology for this report combines primary and secondary approaches to build a structured view of the nasogastric securement device ecosystem. Primary research emphasizes interviews with stakeholders across the value chain, including clinical users involved in tube placement and maintenance, procurement and value analysis participants, and industry executives responsible for product strategy and operations. These conversations focus on use-case requirements, failure modes, evaluation criteria, and adoption barriers, with particular attention to workflow realities in different care settings.

Secondary research synthesizes publicly available technical documentation, regulatory and standards-related information, company disclosures, product instructions for use, and procurement-related materials. This step supports a consistent understanding of device designs, material choices, claims language, and quality considerations, while also clarifying how products are positioned across use environments.

Data triangulation is used to reconcile differing perspectives and reduce bias. Insights from clinicians are cross-checked against supplier capabilities and documented product characteristics, and procurement narratives are validated against observed contracting and standardization practices. The result is an integrated assessment that emphasizes qualitative drivers, competitive positioning, and practical implications for buyers and suppliers.

Throughout the process, the methodology prioritizes clarity and decision utility. The goal is not to overwhelm readers with abstract theory, but to connect observable product attributes and procurement dynamics to the operational outcomes that matter most in enteral therapy management.

Securement choices now carry outsized clinical and operational consequences, making standardization, skin safety, and supply resilience central priorities

Nasogastric securement devices are moving into sharper focus as health systems seek dependable enteral therapy delivery with fewer avoidable interruptions. The category is being reshaped by a stronger emphasis on skin integrity, standardized protocols, and real-world usability, pushing the market beyond generic tapes toward engineered solutions that can perform consistently under moisture, motion, and prolonged wear.

At the same time, policy-driven cost pressures and supply chain uncertainty-particularly around tariffs-are prompting both manufacturers and providers to strengthen resilience. The most successful strategies will combine clinically informed product design, robust training and implementation support, and procurement approaches that prioritize continuity and total workload reduction.

Ultimately, securement is a small device choice with outsized operational consequences. Organizations that treat it as a patient-safety system, measure outcomes, and align stakeholders around standard technique will be best positioned to reduce rework, protect skin, and sustain therapy reliability across care settings.

Note: PDF & Excel + Online Access - 1 Year Show more